Gilead opens new UK headquarters

International biopharmaceutical company Gilead has officially opened its new UK headquarters at Granta Science Park near Cambridge. The building will house the marketing and accounts functions for the UK and Ireland, European IT support, European regulatory affairs department and the European safety reporting department. Gilead employs more than 70 people in the UK.

'Granta Park will be the springboard for our emergence in the UK and Europe as one of the major players in the biopharmaceutical business,' said Gilead general manager Steve Tague. 'In the coming years we expect our products to make a significant impact in advancing therapeutics against life-threatening diseases throughout the world.'

In February the company launched Viread, its 'ground-breaking' HIV treatment. Viread (tenofovir disoproxil fumarate) is a nucleotide reverse transcriptase inhibitor and has achieved EMEA approval for marketing in all 15 EU member states. Gilead's pipeline includes therapeutics for hepatitis B, HIV and antibiotic-resistant bacterial infections.